Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | CMKLR1 | Q99788 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084249 | 0.93 | HRH1 (0.39) | CYP4F2CYP4A11GPR84ALOX5APCMKLR1 | |
| SCHEMBL4088620 | 0.87 | CYP4F2 (0.42) | CYP4F2CYP4A11GPR84ALOX5APPRKDC | |
| SCHEMBL5378043 | 0.86 | RXRA (0.38) | ALOX5APPRKDCCMKLR1KDM1ACYP11B1 | |
| SCHEMBL4082983 | 0.85 | SLC6A2 (0.38) | CYP4F2CYP4A11CMKLR1KDM1A | |
| SCHEMBL4094652 | 0.84 | RAB9A (0.37) | PRKDCCMKLR1KDM1ANPC1MAPK1 | |
| SCHEMBL4091084 | 0.83 | TBK1 (0.41) | HRH1 | |
| SCHEMBL4089935 | 0.83 | CMKLR1 (0.40) | CMKLR1HRH1 | |
| SCHEMBL4093281 | 0.83 | CMKLR1 (0.38) | CYP4F2CYP4A11ALOX5APCMKLR1KDM1A | |
| SCHEMBL4083874 | 0.83 | SCN7A (0.42) | HRH1 | |
| SCHEMBL4079783 | 0.83 | CMKLR1 (0.36) | PRKDCCMKLR1KDM1ANPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791831-A4 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | SIGNAL PHARM LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1791831-A2 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | Signal Pharmaceuticals LLC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051308-A2 | METHODS OF TREATING DISEASES AND DISORDERS BY TARGETING MULTIPLE KINASES | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050107386-A1 | Methods of treating diseases and disorders by targeting multiple kinases | NARLA RAMA KRISHNA (US) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107386-A1 | Methods of treating diseases and disorders by targeting multiple kinases | MAP3K20, MAP3K2, MAP3K1 | CYP4F2 4644/4885CYP4A11 4318/4885GPR84 3110/4885 |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | CYP4F2 3576/4885CYP4A11 1412/4885GPR84 1053/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | CYP4F2 3647/4885CYP4A11 1524/4885GPR84 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.